Global Circular RNA Drugs Market Growth (Status and Outlook) 2026-2032
The global Circular RNA Drugs market size is predicted to grow from US$ 46.96 million in 2025 to US$ 530 million in 2032; it is expected to grow at a CAGR of 41.0% from 2026 to 2032.
Circular RNA drugs are an emerging class of RNA therapeutics that use engineered circular RNA as the core active ingredient or expression vector. These products are generally developed through sequence design, in vitro transcription, circularization, purification, delivery formulation development, and GMP scale-up manufacturing to form drug candidates. Key application areas include therapeutic vaccines, protein-expression therapies, in vivo CAR-T, cancer immunotherapy, ischemic disease repair, and rare disease treatment. Upstream materials mainly include nucleotide raw materials, modified nucleosides, enzymes, plasmid templates, buffers, chromatography media, single-use bioprocessing consumables, lipid nanoparticle materials, analytical testing reagents, and sterile filling and packaging materials. Downstream customers mainly include innovative pharmaceutical companies, RNA drug platform companies, vaccine companies, CRO/CDMO providers, hospital clinical research centers, and collaborative projects with large pharmaceutical companies.
The current circular RNA drugs market remains at an early stage of clinical translation, with industry activity mainly focused on platform validation, candidate selection, circularization process optimization, delivery system development, and clinical safety evaluation. Compared with traditional small-molecule drugs, antibody drugs, and some commercialized mRNA vaccines, circular RNA drugs have not yet established a large-scale end-market sales model. Company value is still mainly reflected in technology platforms, pipeline progress, patent coverage, collaborative R&D capability, and CMC scale-up capability. At this stage, the number of core global players remains limited, with major participants concentrated in the United States and China, while European companies are more active in virus-vector-based circular RNA expression and gene therapy-related directions. Overall, the industry remains an emerging field with high R&D intensity, high technical barriers, and significant uncertainty.
Future development will be centered on the transition from platform concept to clinical validation. Early-stage companies have mainly emphasized the theoretical advantages of circular RNA in stability, expression duration, and programmability, while the next phase of competition will focus more on safety, efficacy, immunogenicity control, and dose-response performance in human studies. As more candidates enter clinical development, the industry is expected to gradually form application clusters around therapeutic vaccines, in vivo cell therapy, local tissue repair, protein-expression therapy, and rare disease treatment. At the same time, circularization efficiency, RNA purity, impurity control, tissue selectivity of LNP or other delivery systems, and consistency in GMP scale-up manufacturing will become key factors determining whether a company can evolve from a research platform into a drug developer.
Market growth is mainly driven by the evolution of RNA drug technologies, unmet clinical needs, capital support, large-pharma collaboration, accumulating regulatory experience, and progress in biomanufacturing processes. Compared with linear mRNA, circular RNA may offer a longer expression window and potentially lower dosing frequency, giving it differentiated value in scenarios that require sustained therapeutic protein expression or localized release of functional factors. Cancer immunotherapy, autoimmune diseases, ischemic cardiovascular diseases, rare diseases, and in vivo CAR-T are likely to become important early validation areas. The growing interest of large pharmaceutical companies in next-generation RNA platforms may also support more licensing deals, acquisitions, and co-development programs, providing small and mid-sized platform companies with funding, clinical development resources, and global registration capabilities.
The main barriers lie in the still-evolving technical maturity, clinical validation, and industrialization pathway. Although circular RNA has potential advantages in molecular stability, its in vivo translation efficiency, delivery efficiency, immune response, long-term safety, and controllability of expression across different tissues still require systematic validation. On the manufacturing side, companies also face challenges related to circularization yield, removal of linear RNA and by-products, batch-to-batch consistency, quality standard development, and cost control. Regulatory review pathways for circular RNA drugs are still being shaped, and differences among technical routes may affect clinical filing and quality-control requirements. Therefore, while the industry has strong long-term growth potential, it is likely to remain R&D-driven in the near term, with significant project differentiation and a high attrition rate.
This report presents a comprehensive overview, market shares, and growth opportunities of Circular RNA Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
Circular RNA drugs are an emerging class of RNA therapeutics that use engineered circular RNA as the core active ingredient or expression vector. These products are generally developed through sequence design, in vitro transcription, circularization, purification, delivery formulation development, and GMP scale-up manufacturing to form drug candidates. Key application areas include therapeutic vaccines, protein-expression therapies, in vivo CAR-T, cancer immunotherapy, ischemic disease repair, and rare disease treatment. Upstream materials mainly include nucleotide raw materials, modified nucleosides, enzymes, plasmid templates, buffers, chromatography media, single-use bioprocessing consumables, lipid nanoparticle materials, analytical testing reagents, and sterile filling and packaging materials. Downstream customers mainly include innovative pharmaceutical companies, RNA drug platform companies, vaccine companies, CRO/CDMO providers, hospital clinical research centers, and collaborative projects with large pharmaceutical companies.
The current circular RNA drugs market remains at an early stage of clinical translation, with industry activity mainly focused on platform validation, candidate selection, circularization process optimization, delivery system development, and clinical safety evaluation. Compared with traditional small-molecule drugs, antibody drugs, and some commercialized mRNA vaccines, circular RNA drugs have not yet established a large-scale end-market sales model. Company value is still mainly reflected in technology platforms, pipeline progress, patent coverage, collaborative R&D capability, and CMC scale-up capability. At this stage, the number of core global players remains limited, with major participants concentrated in the United States and China, while European companies are more active in virus-vector-based circular RNA expression and gene therapy-related directions. Overall, the industry remains an emerging field with high R&D intensity, high technical barriers, and significant uncertainty.
Future development will be centered on the transition from platform concept to clinical validation. Early-stage companies have mainly emphasized the theoretical advantages of circular RNA in stability, expression duration, and programmability, while the next phase of competition will focus more on safety, efficacy, immunogenicity control, and dose-response performance in human studies. As more candidates enter clinical development, the industry is expected to gradually form application clusters around therapeutic vaccines, in vivo cell therapy, local tissue repair, protein-expression therapy, and rare disease treatment. At the same time, circularization efficiency, RNA purity, impurity control, tissue selectivity of LNP or other delivery systems, and consistency in GMP scale-up manufacturing will become key factors determining whether a company can evolve from a research platform into a drug developer.
Market growth is mainly driven by the evolution of RNA drug technologies, unmet clinical needs, capital support, large-pharma collaboration, accumulating regulatory experience, and progress in biomanufacturing processes. Compared with linear mRNA, circular RNA may offer a longer expression window and potentially lower dosing frequency, giving it differentiated value in scenarios that require sustained therapeutic protein expression or localized release of functional factors. Cancer immunotherapy, autoimmune diseases, ischemic cardiovascular diseases, rare diseases, and in vivo CAR-T are likely to become important early validation areas. The growing interest of large pharmaceutical companies in next-generation RNA platforms may also support more licensing deals, acquisitions, and co-development programs, providing small and mid-sized platform companies with funding, clinical development resources, and global registration capabilities.
The main barriers lie in the still-evolving technical maturity, clinical validation, and industrialization pathway. Although circular RNA has potential advantages in molecular stability, its in vivo translation efficiency, delivery efficiency, immune response, long-term safety, and controllability of expression across different tissues still require systematic validation. On the manufacturing side, companies also face challenges related to circularization yield, removal of linear RNA and by-products, batch-to-batch consistency, quality standard development, and cost control. Regulatory review pathways for circular RNA drugs are still being shaped, and differences among technical routes may affect clinical filing and quality-control requirements. Therefore, while the industry has strong long-term growth potential, it is likely to remain R&D-driven in the near term, with significant project differentiation and a high attrition rate.
This report presents a comprehensive overview, market shares, and growth opportunities of Circular RNA Drugs market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Protein Expression Therapeutics
- Therapeutic Vaccines
- Other
- Lipid Nanoparticle Delivery
- Local Direct Delivery
- Other
- Intravenous Administration
- Local Injection
- Other
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Other
- United States
- China%li%
- Europe
- Other regions
- Japan
- South Korea
- Southeast Asia
- Rest of world
- Orna Therapeutics
- RiboX Therapeutics
- Sail Biomedicines
- Chimerna Therapeutics
- Torque Bio
- Circurna
- Shanghai CirCode Biomed
- Therorna
- Circio Holding
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Circular RNA Drugs Market Size 2026-2032
2.1.2 Circular RNA Drugs Market Size CAGR by Region
2.2 Circular RNA Drugs Segment by Type
2.2.1 Protein Expression Therapeutics
2.2.2 Therapeutic Vaccines
2.2.3 Other
2.2.4 Circular RNA Drugs Market Size by Type
2.2.4.1 Global Circular RNA Drugs Market Size Market Share by Type (2026-2032)
2.2.4.2 Global Circular RNA Drugs Market Size Growth Rate by Type (2026-2032)
2.3 Circular RNA Drugs Segment by Delivery Technology
2.3.1 Lipid Nanoparticle Delivery
2.3.2 Local Direct Delivery
2.3.3 Other
2.3.4 Circular RNA Drugs Market Size by Delivery Technology
2.3.4.1 Global Circular RNA Drugs Market Size Market Share by Delivery Technology (2026-2032)
2.3.4.2 Global Circular RNA Drugs Market Size Growth Rate by Delivery Technology (2026-2032)
2.4 Circular RNA Drugs Segment by Route of Administration
2.4.1 Intravenous Administration
2.4.2 Local Injection
2.4.3 Other
2.4.4 Circular RNA Drugs Market Size by Route of Administration
2.4.4.1 Global Circular RNA Drugs Market Size Market Share by Route of Administration (2026-2032)
2.4.4.2 Global Circular RNA Drugs Market Size Growth Rate by Route of Administration (2026-2032)
2.5 Circular RNA Drugs Segment by Application
2.5.1 Pharmaceutical and Biotechnology Companies
2.5.2 Research Institutes
2.5.3 Other
2.5.4 Circular RNA Drugs Market Size by Application (2026-2032)
2.5.4.1 Global Circular RNA Drugs Market Size Market Share by Application (2026-2032)
2.5.4.2 Global Circular RNA Drugs Market Size Growth Rate by Application (2026-2032)
3 CIRCULAR RNA DRUGS KEY PLAYERS
3.1 Date of Key Players Enter into Circular RNA Drugs
3.2 Key Players Circular RNA Drugs Product Offered
3.3 Key Players Circular RNA Drugs Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players Circular RNA Drugs Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 CIRCULAR RNA DRUGS BY REGIONS
4.1 Circular RNA Drugs Market Size by Regions (2026-2032)
4.2 United States Circular RNA Drugs Market Size Growth (2026-2032)
4.3 China Circular RNA Drugs Market Size Growth (2026-2032)
4.4 Europe Circular RNA Drugs Market Size Growth (2026-2032)
4.5 Rest of World Circular RNA Drugs Market Size Growth (2026-2032)
5 UNITED STATES
5.1 United States Circular RNA Drugs Market Size by Type (2026-2032)
5.2 United States Circular RNA Drugs Market Size by Application (2026-2032)
6 EUROPE
6.1 Europe Circular RNA Drugs Market Size by Type (2026-2032)
6.2 Europe Circular RNA Drugs Market Size by Application (2026-2032)
7 CHINA
7.1 China Circular RNA Drugs Market Size by Type (2026-2032)
7.2 China Circular RNA Drugs Market Size by Application (2026-2032)
8 REST OF WORLD
8.1 Rest of World Circular RNA Drugs Market Size by Type (2026-2032)
8.2 Rest of World Circular RNA Drugs Market Size by Application (2026-2032)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 KEY INVESTORS IN CIRCULAR RNA DRUGS
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and Market Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and Market Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 ??
11 KEY PLAYERS ANALYSIS
11.1 Orna Therapeutics
11.1.1 Orna Therapeutics Company Details
11.1.2 Orna Therapeutics Circular RNA Drugs Product Offered
11.1.3 Orna Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
11.1.4 Orna Therapeutics Main Business Overview
11.1.5 Orna Therapeutics News
11.2 RiboX Therapeutics
11.2.1 RiboX Therapeutics Company Details
11.2.2 RiboX Therapeutics Circular RNA Drugs Product Offered
11.2.3 RiboX Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
11.2.4 RiboX Therapeutics Main Business Overview
11.2.5 RiboX Therapeutics News
11.3 Sail Biomedicines
11.3.1 Sail Biomedicines Company Details
11.3.2 Sail Biomedicines Circular RNA Drugs Product Offered
11.3.3 Sail Biomedicines Circular RNA Drugs Market Size (2025 VS 2031)
11.3.4 Sail Biomedicines Main Business Overview
11.3.5 Sail Biomedicines News
11.4 Chimerna Therapeutics
11.4.1 Chimerna Therapeutics Company Details
11.4.2 Chimerna Therapeutics Circular RNA Drugs Product Offered
11.4.3 Chimerna Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
11.4.4 Chimerna Therapeutics Main Business Overview
11.4.5 Chimerna Therapeutics News
11.5 Torque Bio
11.5.1 Torque Bio Company Details
11.5.2 Torque Bio Circular RNA Drugs Product Offered
11.5.3 Torque Bio Circular RNA Drugs Market Size (2025 VS 2031)
11.5.4 Torque Bio Main Business Overview
11.5.5 Torque Bio News
11.6 Circurna
11.6.1 Circurna Company Details
11.6.2 Circurna Circular RNA Drugs Product Offered
11.6.3 Circurna Circular RNA Drugs Market Size (2025 VS 2031)
11.6.4 Circurna Main Business Overview
11.6.5 Circurna News
11.7 Shanghai CirCode Biomed
11.7.1 Shanghai CirCode Biomed Company Details
11.7.2 Shanghai CirCode Biomed Circular RNA Drugs Product Offered
11.7.3 Shanghai CirCode Biomed Circular RNA Drugs Market Size (2025 VS 2031)
11.7.4 Shanghai CirCode Biomed Main Business Overview
11.7.5 Shanghai CirCode Biomed News
11.8 Therorna
11.8.1 Therorna Company Details
11.8.2 Therorna Circular RNA Drugs Product Offered
11.8.3 Therorna Circular RNA Drugs Market Size (2025 VS 2031)
11.8.4 Therorna Main Business Overview
11.8.5 Therorna News
11.9 Circio Holding
11.9.1 Circio Holding Company Details
11.9.2 Circio Holding Circular RNA Drugs Product Offered
11.9.3 Circio Holding Circular RNA Drugs Market Size (2025 VS 2031)
11.9.4 Circio Holding Main Business Overview
11.9.5 Circio Holding News
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Circular RNA Drugs Market Size 2026-2032
2.1.2 Circular RNA Drugs Market Size CAGR by Region
2.2 Circular RNA Drugs Segment by Type
2.2.1 Protein Expression Therapeutics
2.2.2 Therapeutic Vaccines
2.2.3 Other
2.2.4 Circular RNA Drugs Market Size by Type
2.2.4.1 Global Circular RNA Drugs Market Size Market Share by Type (2026-2032)
2.2.4.2 Global Circular RNA Drugs Market Size Growth Rate by Type (2026-2032)
2.3 Circular RNA Drugs Segment by Delivery Technology
2.3.1 Lipid Nanoparticle Delivery
2.3.2 Local Direct Delivery
2.3.3 Other
2.3.4 Circular RNA Drugs Market Size by Delivery Technology
2.3.4.1 Global Circular RNA Drugs Market Size Market Share by Delivery Technology (2026-2032)
2.3.4.2 Global Circular RNA Drugs Market Size Growth Rate by Delivery Technology (2026-2032)
2.4 Circular RNA Drugs Segment by Route of Administration
2.4.1 Intravenous Administration
2.4.2 Local Injection
2.4.3 Other
2.4.4 Circular RNA Drugs Market Size by Route of Administration
2.4.4.1 Global Circular RNA Drugs Market Size Market Share by Route of Administration (2026-2032)
2.4.4.2 Global Circular RNA Drugs Market Size Growth Rate by Route of Administration (2026-2032)
2.5 Circular RNA Drugs Segment by Application
2.5.1 Pharmaceutical and Biotechnology Companies
2.5.2 Research Institutes
2.5.3 Other
2.5.4 Circular RNA Drugs Market Size by Application (2026-2032)
2.5.4.1 Global Circular RNA Drugs Market Size Market Share by Application (2026-2032)
2.5.4.2 Global Circular RNA Drugs Market Size Growth Rate by Application (2026-2032)
3 CIRCULAR RNA DRUGS KEY PLAYERS
3.1 Date of Key Players Enter into Circular RNA Drugs
3.2 Key Players Circular RNA Drugs Product Offered
3.3 Key Players Circular RNA Drugs Funding/Investment Analysis
3.4 Funding/Investment
3.4.1 Funding/Investment by Regions
3.4.2 Funding/Investment by End-Industry
3.5 Key Players Circular RNA Drugs Valuation & Market Capitalization
3.6 Key Players Mergers & Acquisitions, Expansion Plans
3.7 Market Ranking
3.8 New Product/Technology Launches
3.9 Partnerships, Agreements, and Collaborations
3.10 Mergers and Acquisitions
4 CIRCULAR RNA DRUGS BY REGIONS
4.1 Circular RNA Drugs Market Size by Regions (2026-2032)
4.2 United States Circular RNA Drugs Market Size Growth (2026-2032)
4.3 China Circular RNA Drugs Market Size Growth (2026-2032)
4.4 Europe Circular RNA Drugs Market Size Growth (2026-2032)
4.5 Rest of World Circular RNA Drugs Market Size Growth (2026-2032)
5 UNITED STATES
5.1 United States Circular RNA Drugs Market Size by Type (2026-2032)
5.2 United States Circular RNA Drugs Market Size by Application (2026-2032)
6 EUROPE
6.1 Europe Circular RNA Drugs Market Size by Type (2026-2032)
6.2 Europe Circular RNA Drugs Market Size by Application (2026-2032)
7 CHINA
7.1 China Circular RNA Drugs Market Size by Type (2026-2032)
7.2 China Circular RNA Drugs Market Size by Application (2026-2032)
8 REST OF WORLD
8.1 Rest of World Circular RNA Drugs Market Size by Type (2026-2032)
8.2 Rest of World Circular RNA Drugs Market Size by Application (2026-2032)
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 KEY INVESTORS IN CIRCULAR RNA DRUGS
10.1 Company A
10.1.1 Company A Company Details
10.1.2 Company Description
10.1.3 Companies Invested by Company A
10.1.4 Company A Key Development and Market Layout
10.2 Company B
10.2.1 Company B Company Details
10.2.2 Company Description
10.2.3 Companies Invested by Company B
10.2.4 Company B Key Development and Market Layout
10.3 Company C
10.3.1 Company C Company Details
10.3.2 Company Description
10.3.3 Companies Invested by Company C
10.3.4 Company C Key Development and Market Layout
10.4 Company D
10.5 ??
11 KEY PLAYERS ANALYSIS
11.1 Orna Therapeutics
11.1.1 Orna Therapeutics Company Details
11.1.2 Orna Therapeutics Circular RNA Drugs Product Offered
11.1.3 Orna Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
11.1.4 Orna Therapeutics Main Business Overview
11.1.5 Orna Therapeutics News
11.2 RiboX Therapeutics
11.2.1 RiboX Therapeutics Company Details
11.2.2 RiboX Therapeutics Circular RNA Drugs Product Offered
11.2.3 RiboX Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
11.2.4 RiboX Therapeutics Main Business Overview
11.2.5 RiboX Therapeutics News
11.3 Sail Biomedicines
11.3.1 Sail Biomedicines Company Details
11.3.2 Sail Biomedicines Circular RNA Drugs Product Offered
11.3.3 Sail Biomedicines Circular RNA Drugs Market Size (2025 VS 2031)
11.3.4 Sail Biomedicines Main Business Overview
11.3.5 Sail Biomedicines News
11.4 Chimerna Therapeutics
11.4.1 Chimerna Therapeutics Company Details
11.4.2 Chimerna Therapeutics Circular RNA Drugs Product Offered
11.4.3 Chimerna Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
11.4.4 Chimerna Therapeutics Main Business Overview
11.4.5 Chimerna Therapeutics News
11.5 Torque Bio
11.5.1 Torque Bio Company Details
11.5.2 Torque Bio Circular RNA Drugs Product Offered
11.5.3 Torque Bio Circular RNA Drugs Market Size (2025 VS 2031)
11.5.4 Torque Bio Main Business Overview
11.5.5 Torque Bio News
11.6 Circurna
11.6.1 Circurna Company Details
11.6.2 Circurna Circular RNA Drugs Product Offered
11.6.3 Circurna Circular RNA Drugs Market Size (2025 VS 2031)
11.6.4 Circurna Main Business Overview
11.6.5 Circurna News
11.7 Shanghai CirCode Biomed
11.7.1 Shanghai CirCode Biomed Company Details
11.7.2 Shanghai CirCode Biomed Circular RNA Drugs Product Offered
11.7.3 Shanghai CirCode Biomed Circular RNA Drugs Market Size (2025 VS 2031)
11.7.4 Shanghai CirCode Biomed Main Business Overview
11.7.5 Shanghai CirCode Biomed News
11.8 Therorna
11.8.1 Therorna Company Details
11.8.2 Therorna Circular RNA Drugs Product Offered
11.8.3 Therorna Circular RNA Drugs Market Size (2025 VS 2031)
11.8.4 Therorna Main Business Overview
11.8.5 Therorna News
11.9 Circio Holding
11.9.1 Circio Holding Company Details
11.9.2 Circio Holding Circular RNA Drugs Product Offered
11.9.3 Circio Holding Circular RNA Drugs Market Size (2025 VS 2031)
11.9.4 Circio Holding Main Business Overview
11.9.5 Circio Holding News
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Circular RNA Drugs Market Size CAGR by Region (2026-2032) ($ millions)
Table 2. Major Players of Protein Expression Therapeutics
Table 3. Major Players of Therapeutic Vaccines
Table 4. Major Players of Other
Table 5. Global Market Size by Type (2026-2032) ($ millions)
Table 6. Global Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Table 7. Major Players of Lipid Nanoparticle Delivery
Table 8. Major Players of Local Direct Delivery
Table 9. Major Players of Other
Table 10. Global Market Size by Delivery Technology (2026-2032) ($ millions)
Table 11. Global Circular RNA Drugs Market Size Market Share by Delivery Technology (2026-2032)
Table 12. Major Players of Intravenous Administration
Table 13. Major Players of Local Injection
Table 14. Major Players of Other
Table 15. Global Market Size by Route of Administration (2026-2032) ($ millions)
Table 16. Global Circular RNA Drugs Market Size Market Share by Route of Administration (2026-2032)
Table 17. Global Circular RNA Drugs Market Size by Application (2026-2032) ($ millions)
Table 18. Global Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Table 19. Date of Global Key Players Enter into Circular RNA Drugs Market
Table 20. Global Key Players Circular RNA Drugs Product Offered
Table 21. Key Players Circular RNA Drugs Funding/Investment (Million USD)
Table 22. Funding/Investment by Regions
Table 23. Funding/Investment by End-Industry
Table 24. Key Players Circular RNA Drugs Valuation & Market Capitalization (Million USD)
Table 25. Key Players Mergers & Acquisitions, Expansion Plans
Table 26. Circular RNA Drugs New Product/Technology Launches
Table 27. Circular RNA Drugs Industry Partnerships, Agreements, and Collaborations
Table 28. Circular RNA Drugs Industry Mergers and Acquisitions
Table 29. Global Circular RNA Drugs Market Size by Regions 2026-2032 ($ millions)
Table 30. Global Circular RNA Drugs Market Size Market Share by Regions 2026-2032
Table 31. United States Circular RNA Drugs Market Size by Type (2026-2032) ($ millions)
Table 32. United States Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Table 33. United States Circular RNA Drugs Market Size by Application (2026-2032) ($ millions)
Table 34. United States Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Table 35. Europe Circular RNA Drugs Market Size by Type (2026-2032) ($ millions)
Table 36. Europe Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Table 37. Europe Circular RNA Drugs Market Size by Application (2026-2032) ($ millions)
Table 38. Europe Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Table 39. China Circular RNA Drugs Market Size by Type (2026-2032) ($ millions)
Table 40. China Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Table 41. China Circular RNA Drugs Market Size by Application (2026-2032) ($ millions)
Table 42. China Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Table 43. Rest of World Circular RNA Drugs Market Size by Type (2026-2032) ($ millions)
Table 44. Rest of World Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Table 45. Rest of World Circular RNA Drugs Market Size by Application (2026-2032) ($ millions)
Table 46. Rest of World Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Table 47. Key Market Drivers & Growth Opportunities of Circular RNA Drugs
Table 48. Key Market Challenges & Risks of Circular RNA Drugs
Table 49. Key Industry Trends of Circular RNA Drugs
Table 50. Company A Company Details
Table 51. Companies Invested by Company A
Table 52. Company A Key Development and Market Layout
Table 53. Company B Company Details
Table 54. Companies Invested by Company B
Table 55. Company B Key Development and Market Layout
Table 56. Company C Company Details
Table 57. Companies Invested by Company C
Table 58. Company C Key Development and Market Layout
Table 59. Orna Therapeutics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 60. Orna Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
Table 61. RiboX Therapeutics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 62. RiboX Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
Table 63. Sail Biomedicines Basic Information, Head Office, Major Market Areas and Its Competitors
Table 64. Sail Biomedicines Circular RNA Drugs Market Size (2025 VS 2031)
Table 65. Chimerna Therapeutics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 66. Chimerna Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
Table 67. Torque Bio Basic Information, Head Office, Major Market Areas and Its Competitors
Table 68. Torque Bio Circular RNA Drugs Market Size (2025 VS 2031)
Table 69. Circurna Basic Information, Head Office, Major Market Areas and Its Competitors
Table 70. Circurna Circular RNA Drugs Market Size (2025 VS 2031)
Table 71. Shanghai CirCode Biomed Basic Information, Head Office, Major Market Areas and Its Competitors
Table 72. Shanghai CirCode Biomed Circular RNA Drugs Market Size (2025 VS 2031)
Table 73. Therorna Basic Information, Head Office, Major Market Areas and Its Competitors
Table 74. Therorna Circular RNA Drugs Market Size (2025 VS 2031)
Table 75. Circio Holding Basic Information, Head Office, Major Market Areas and Its Competitors
Table 76. Circio Holding Circular RNA Drugs Market Size (2025 VS 2031)
Table 1. Circular RNA Drugs Market Size CAGR by Region (2026-2032) ($ millions)
Table 2. Major Players of Protein Expression Therapeutics
Table 3. Major Players of Therapeutic Vaccines
Table 4. Major Players of Other
Table 5. Global Market Size by Type (2026-2032) ($ millions)
Table 6. Global Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Table 7. Major Players of Lipid Nanoparticle Delivery
Table 8. Major Players of Local Direct Delivery
Table 9. Major Players of Other
Table 10. Global Market Size by Delivery Technology (2026-2032) ($ millions)
Table 11. Global Circular RNA Drugs Market Size Market Share by Delivery Technology (2026-2032)
Table 12. Major Players of Intravenous Administration
Table 13. Major Players of Local Injection
Table 14. Major Players of Other
Table 15. Global Market Size by Route of Administration (2026-2032) ($ millions)
Table 16. Global Circular RNA Drugs Market Size Market Share by Route of Administration (2026-2032)
Table 17. Global Circular RNA Drugs Market Size by Application (2026-2032) ($ millions)
Table 18. Global Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Table 19. Date of Global Key Players Enter into Circular RNA Drugs Market
Table 20. Global Key Players Circular RNA Drugs Product Offered
Table 21. Key Players Circular RNA Drugs Funding/Investment (Million USD)
Table 22. Funding/Investment by Regions
Table 23. Funding/Investment by End-Industry
Table 24. Key Players Circular RNA Drugs Valuation & Market Capitalization (Million USD)
Table 25. Key Players Mergers & Acquisitions, Expansion Plans
Table 26. Circular RNA Drugs New Product/Technology Launches
Table 27. Circular RNA Drugs Industry Partnerships, Agreements, and Collaborations
Table 28. Circular RNA Drugs Industry Mergers and Acquisitions
Table 29. Global Circular RNA Drugs Market Size by Regions 2026-2032 ($ millions)
Table 30. Global Circular RNA Drugs Market Size Market Share by Regions 2026-2032
Table 31. United States Circular RNA Drugs Market Size by Type (2026-2032) ($ millions)
Table 32. United States Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Table 33. United States Circular RNA Drugs Market Size by Application (2026-2032) ($ millions)
Table 34. United States Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Table 35. Europe Circular RNA Drugs Market Size by Type (2026-2032) ($ millions)
Table 36. Europe Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Table 37. Europe Circular RNA Drugs Market Size by Application (2026-2032) ($ millions)
Table 38. Europe Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Table 39. China Circular RNA Drugs Market Size by Type (2026-2032) ($ millions)
Table 40. China Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Table 41. China Circular RNA Drugs Market Size by Application (2026-2032) ($ millions)
Table 42. China Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Table 43. Rest of World Circular RNA Drugs Market Size by Type (2026-2032) ($ millions)
Table 44. Rest of World Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Table 45. Rest of World Circular RNA Drugs Market Size by Application (2026-2032) ($ millions)
Table 46. Rest of World Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Table 47. Key Market Drivers & Growth Opportunities of Circular RNA Drugs
Table 48. Key Market Challenges & Risks of Circular RNA Drugs
Table 49. Key Industry Trends of Circular RNA Drugs
Table 50. Company A Company Details
Table 51. Companies Invested by Company A
Table 52. Company A Key Development and Market Layout
Table 53. Company B Company Details
Table 54. Companies Invested by Company B
Table 55. Company B Key Development and Market Layout
Table 56. Company C Company Details
Table 57. Companies Invested by Company C
Table 58. Company C Key Development and Market Layout
Table 59. Orna Therapeutics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 60. Orna Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
Table 61. RiboX Therapeutics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 62. RiboX Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
Table 63. Sail Biomedicines Basic Information, Head Office, Major Market Areas and Its Competitors
Table 64. Sail Biomedicines Circular RNA Drugs Market Size (2025 VS 2031)
Table 65. Chimerna Therapeutics Basic Information, Head Office, Major Market Areas and Its Competitors
Table 66. Chimerna Therapeutics Circular RNA Drugs Market Size (2025 VS 2031)
Table 67. Torque Bio Basic Information, Head Office, Major Market Areas and Its Competitors
Table 68. Torque Bio Circular RNA Drugs Market Size (2025 VS 2031)
Table 69. Circurna Basic Information, Head Office, Major Market Areas and Its Competitors
Table 70. Circurna Circular RNA Drugs Market Size (2025 VS 2031)
Table 71. Shanghai CirCode Biomed Basic Information, Head Office, Major Market Areas and Its Competitors
Table 72. Shanghai CirCode Biomed Circular RNA Drugs Market Size (2025 VS 2031)
Table 73. Therorna Basic Information, Head Office, Major Market Areas and Its Competitors
Table 74. Therorna Circular RNA Drugs Market Size (2025 VS 2031)
Table 75. Circio Holding Basic Information, Head Office, Major Market Areas and Its Competitors
Table 76. Circio Holding Circular RNA Drugs Market Size (2025 VS 2031)
LIST OF FIGURES
Figure 1. Picture of Circular RNA Drugs
Figure 2. Circular RNA Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Circular RNA Drugs Market Size Growth Rate 2026-2032 ($ millions)
Figure 7. Circular RNA Drugs Market Size by Region (2025 & 2032) ($ millions)
Figure 8. Global Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Figure 9. Global Protein Expression Therapeutics Market Size Growth Rate
Figure 10. Global Therapeutic Vaccines Market Size Growth Rate
Figure 11. Global Circular RNA Drugs Market Size Market Share by Delivery Technology (2026-2032)
Figure 12. Global Lipid Nanoparticle Delivery Market Size Growth Rate
Figure 13. Global Local Direct Delivery Market Size Growth Rate
Figure 14. Global Circular RNA Drugs Market Size Market Share by Route of Administration (2026-2032)
Figure 15. Global Intravenous Administration Market Size Growth Rate
Figure 16. Global Local Injection Market Size Growth Rate
Figure 17. Circular RNA Drugs in Pharmaceutical and Biotechnology Companies
Figure 18. Global Circular RNA Drugs Market: Pharmaceutical and Biotechnology Companies (2026-2032) ($ millions)
Figure 19. Circular RNA Drugs in Research Institutes
Figure 20. Global Circular RNA Drugs Market: Research Institutes (2026-2032) ($ millions)
Figure 21. Circular RNA Drugs in Other
Figure 22. Global Circular RNA Drugs Market: Other (2026-2032) ($ millions)
Figure 23. Global Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Figure 24. Global Circular RNA Drugs Market Size in Pharmaceutical and Biotechnology Companies Growth Rate
Figure 25. Global Circular RNA Drugs Market Size in Research Institutes Growth Rate
Figure 26. Funding/Investment
Figure 27. Global Circular RNA Drugs Market Size Market Share by Regions 2026-2032
Figure 28. United States Circular RNA Drugs Market Size 2026-2032 ($ millions)
Figure 29. China Circular RNA Drugs Market Size 2026-2032 ($ millions)
Figure 30. Europe Circular RNA Drugs Market Size 2026-2032 ($ millions)
Figure 31. Rest of World Circular RNA Drugs Market Size 2026-2032 ($ millions)
Figure 32. United States Circular RNA Drugs Consumption Market Share by Type in 2030
Figure 33. United States Circular RNA Drugs Market Size Market Share by Application in 2030
Figure 34. Europe Circular RNA Drugs Consumption Market Share by Type in 2030
Figure 35. Europe Circular RNA Drugs Market Size Market Share by Application in 2030
Figure 36. China Circular RNA Drugs Consumption Market Share by Type in 2030
Figure 37. China Circular RNA Drugs Market Size Market Share by Application in 2030
Figure 38. Rest of World Circular RNA Drugs Consumption Market Share by Type in 2030
Figure 39. Rest of World Circular RNA Drugs Market Size Market Share by Application in 2030
Figure 1. Picture of Circular RNA Drugs
Figure 2. Circular RNA Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Circular RNA Drugs Market Size Growth Rate 2026-2032 ($ millions)
Figure 7. Circular RNA Drugs Market Size by Region (2025 & 2032) ($ millions)
Figure 8. Global Circular RNA Drugs Market Size Market Share by Type (2026-2032)
Figure 9. Global Protein Expression Therapeutics Market Size Growth Rate
Figure 10. Global Therapeutic Vaccines Market Size Growth Rate
Figure 11. Global Circular RNA Drugs Market Size Market Share by Delivery Technology (2026-2032)
Figure 12. Global Lipid Nanoparticle Delivery Market Size Growth Rate
Figure 13. Global Local Direct Delivery Market Size Growth Rate
Figure 14. Global Circular RNA Drugs Market Size Market Share by Route of Administration (2026-2032)
Figure 15. Global Intravenous Administration Market Size Growth Rate
Figure 16. Global Local Injection Market Size Growth Rate
Figure 17. Circular RNA Drugs in Pharmaceutical and Biotechnology Companies
Figure 18. Global Circular RNA Drugs Market: Pharmaceutical and Biotechnology Companies (2026-2032) ($ millions)
Figure 19. Circular RNA Drugs in Research Institutes
Figure 20. Global Circular RNA Drugs Market: Research Institutes (2026-2032) ($ millions)
Figure 21. Circular RNA Drugs in Other
Figure 22. Global Circular RNA Drugs Market: Other (2026-2032) ($ millions)
Figure 23. Global Circular RNA Drugs Market Size Market Share by Application (2026-2032)
Figure 24. Global Circular RNA Drugs Market Size in Pharmaceutical and Biotechnology Companies Growth Rate
Figure 25. Global Circular RNA Drugs Market Size in Research Institutes Growth Rate
Figure 26. Funding/Investment
Figure 27. Global Circular RNA Drugs Market Size Market Share by Regions 2026-2032
Figure 28. United States Circular RNA Drugs Market Size 2026-2032 ($ millions)
Figure 29. China Circular RNA Drugs Market Size 2026-2032 ($ millions)
Figure 30. Europe Circular RNA Drugs Market Size 2026-2032 ($ millions)
Figure 31. Rest of World Circular RNA Drugs Market Size 2026-2032 ($ millions)
Figure 32. United States Circular RNA Drugs Consumption Market Share by Type in 2030
Figure 33. United States Circular RNA Drugs Market Size Market Share by Application in 2030
Figure 34. Europe Circular RNA Drugs Consumption Market Share by Type in 2030
Figure 35. Europe Circular RNA Drugs Market Size Market Share by Application in 2030
Figure 36. China Circular RNA Drugs Consumption Market Share by Type in 2030
Figure 37. China Circular RNA Drugs Market Size Market Share by Application in 2030
Figure 38. Rest of World Circular RNA Drugs Consumption Market Share by Type in 2030
Figure 39. Rest of World Circular RNA Drugs Market Size Market Share by Application in 2030
